Travere Therapeutics, Inc.TVTXNASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank93
3Y CAGR+7.3%
5Y CAGR+7.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+7.3%/yr
vs +16.9%/yr prior
5Y CAGR
+7.3%/yr
Consistent
Acceleration
-9.6pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | $525.08M | -4.4% |
| 2024 | $549.26M | +5.2% |
| 2023 | $521.93M | +22.8% |
| 2022 | $424.85M | +29.7% |
| 2021 | $327.44M | -11.1% |
| 2020 | $368.36M | +36.5% |
| 2019 | $269.91M | +18.7% |
| 2018 | $227.41M | +24.9% |
| 2017 | $182.13M | +7.9% |
| 2016 | $168.87M | - |